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Objectives: To evaluate the influence of the practice
setting on diagnostic accuracy of fractional exhaled
nitric oxide (FENO) for diagnosing asthma; and to
develop prediction rules for diagnostic decision-making
including clinical signs and symptoms (CSS).
Setting: Patients from 10 general practices and 1
private practice of 5 pneumologists in ambulatory care.
Participants: 553 patients, 57.9% female.
Consecutive inclusion of diagnostic-naive patients
suspected of suffering from obstructive airway disease.
Exclusion criteria were respiratory tract infections
within the last 6 weeks.
Interventions: The index test was FENO
measurement. Reference standard was the Tiffeneau
ratio (forced expiratory volume in 1 s/vital capacity) or
airway resistance as assessed by whole body
plethysmography, with additional bronchoprovocation
or bronchodilator testing.
Primary and secondary outcome measures:
Asthma as determined by pneumologists, who were
blind to FENO measurement results. Prediction rules
were derived from multiple logistic regression analysis.
A freely available calculator that allows computing all
combinations was developed.
Results: The practice setting only had minor influence
on sensitivities of FENO cut-off points. In the final
model (n=472), allergic rhinitis, wheezing and previous
medication were positively associated with asthma.
Increasing age and recurrent respiratory tract infections
were negatively associated. The area under the curve
(AUC) of FENO (AUC=0.650; 95% CI 0.599 to 0.701)
increased significantly (p<0.0001) when combined
with CSS (AUC=0.753; 95% CI 0.707 to 0.798).
Presence of wheezing and allergic rhinitis allowed
ruling in asthma with FENO >30 ppb. Ruling out with
FENO <16 ppb in patients <43 years was only possible
without allergic symptoms when recurrent respiratory
tract infections were present.
Conclusions: FENO results should be interpreted in
the context of CSS to enhance their diagnostic value in
primary care. The final diagnostic model appears as a
sound algorithm fitting well to the established
diagnostic rules related to CSS of asthma. FENO
appears more effective for ruling in asthma than for
ruling it out.
INTRODUCTION
Asthma is a common chronic disease with a
prevalence of up to 5% in industrialised
countries. It is characterised by chronic
inflammation, bronchial hyper-responsiveness
(BHR) and usually reversible airway obstruc-
tion. Many efforts continue to be undertaken
to improve the diagnostic process to allow an
early diagnosis, as early treatment is import-
ant for the management of the disease.
Investigation of the diagnostic accuracy of
clinical signs and symptoms (CSS) showed
that these were not very effective in ruling in
or ruling out the disease.1 2 Spirometry is
considered a reference standard for
Strengths and limitations of this study
▪ We used data from 553 patients to develop pre-
diction rules for diagnostic decision-making with
fractional exhaled nitric oxide (FENO) measure-
ment including clinical signs and symptoms.
▪ The general practice patients seemed to be
selected more than those of the pneumologists’
practice, which might be explained by the study
design. Therefore, it appeared adequate to
extrapolate our FENO findings more cautiously to
allow generalisation of the diagnostic algorithm.
▪ The final model fitted well with the established
clinical decision rules used by many physicians
and led to a more conservative interpretation of
the FENO measurements. However, a validation
study would be desirable to confirm our
findings.
▪ We used the maximum concentration of metha-
choline for bronchial provocation as a reference
standard to rule in and rule out asthma.
Therefore, the potential of FENO for ruling out
moderate and severe asthma might be
underestimated.
▪ A freely available calculator that allows computa-
tion of the probability of asthma based on the
combination of clinical signs and symptoms, and
FENO results, was developed.
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diagnosing airway obstruction,3 but it is not possible to
rule out milder forms of asthma, as obstruction is not
present in these cases.4 Guidelines also suggest the use of
peak flow variability to diagnose BHR,5 but its diagnostic
accuracy is low.6 Therefore, bronchoprovocation for
determining BHR still remains as a reference standard,
particularly in cases with inconclusive spirometric
results.7 It is considered valuable in confirming or
excluding asthma, despite being a time-consuming and
costly, and not always available, procedure, and carrying a
small risk of severe bronchospasm.8
Compared to bronchoprovocation, fractional exhaled
nitric oxide (FENO) is an easily available, truly non-
invasive marker. Increased FENO has been consistently
demonstrated in asthma, including milder stages of the
disease.9 10 The major pathophysiological basis seems to
be that nitric oxide has a modulatory role in airway
hyper-responsiveness11 and eosinophilic airway inflam-
mation.12 Therefore, FENO has a potential in identify-
ing specific asthma phenotypes, which might also allow
the prediction of steroid responsiveness due to eosino-
philic inflammation.13 This might be especially helpful
for establishing or confirming the diagnosis safely and
quickly in the primary care setting. Its diagnostic accur-
acy has been investigated in a large number of studies.
In general, the results were promising, but different
cut-off points were suggested to rule in or rule out
asthma. As an example, to rule in the diagnosis of
asthma with FENO, >50 parts per billion (ppb),14 15 or
FENO >35 ppb,16 or FENO >46 ppb, has been sug-
gested.17 To rule out the disease with FENO, <15–25 ppb
has been suggested.14 FENO <16 ppb17 or even lower18
might be more useful in the primary care setting.
An important reason for the variation in cut-off points
might be the selection of patients who participated in
the diagnostic studies. The influence of the patient spec-
trum on the variation of diagnostic accuracy was already
demonstrated by Ransohoff and Feinstein.19
Knottnerus20 explained the increase of sensitivity and
decrease of specificity by referral processes in a meth-
odological framework. The understanding of this
process is important as patients present to the general
practitioner (GP) with early symptoms and thus often
with lower severity of disease.21 Beyond that, the inter-
pretation of a test result is often hampered by low posi-
tive predictive values of tests, because the pretest
probability of the target disease is often low in general
practice. This phenomenon is described by Bayes’
Theorem.22 Especially in the primary care setting, in
which few objective methods are available, it seems rea-
sonable to combine information from a diagnostic test
with the CSS presented by the individual patient, to
enhance the diagnostic accuracy. This approach has
been followed previously, for example, for pneumonia
and C reactive protein.23 24 The aim of the present study
was to evaluate the influence of patient selection on the
diagnostic accuracy of FENO measurement on the basis
of two diagnostic studies from different clinical
settings,17 18 and to develop prediction rules including
CSS in order to enhance the diagnostic value.
METHODS
Design and sample
The first part of this prospective diagnostic study was
performed in 10 German general practices in the area
of Heidelberg in Baden-Württemberg, between February
2006 and June 2007.17 Two hundred and ten patients vis-
iting their GP for the first time, with symptoms suggest-
ive of OAD (obstructive airway disease) or the respective
differential diagnoses (such as restrictive airway disease),
were included consecutively. The patients had to present
with symptoms such as dyspnoea, cough or expector-
ation of more than two months, thus leading to the clin-
ical suspicion of obstructive or restrictive airway disease
as the most important differential diagnoses. The pres-
ence of at least one of these symptoms was used as inclu-
sion criterion (indicated population design).25 GPs were
advised to exclude patients who had suffered from
respiratory tract infections within 6 weeks preceding the
evaluation. After the initial judgement by the GP,
patients were sent to the lung function laboratory of the
University Medical Hospital for diagnostic assessment
including FENO measurement. Patients with a previ-
ously established diagnosis of OAD were excluded.
Other exclusion criteria related to known contraindica-
tions for bronchodilator reversibility testing or bronchial
provocation, namely untreated hyperthyreosis, unstable
coronary artery disease and cardiac arrhythmia.
Pregnancy also led to exclusion. Medical history was
recorded using a structured questionnaire (table 1).
The second part of the study was performed in a
private practice of five pneumologists in Bavaria,
between June 2010 and October 2011.18 In Germany,
specialists also work in primary care in their private prac-
tices, and ambulatory care comprises almost all specia-
lists. There is no formal gatekeeping role for a GP in the
German healthcare system. However, referrals from a GP
to a specialist are requested in most cases. Only patients
presenting for the first time for diagnostic work up to
include or exclude an OAD or the respective differential
diagnoses, were included. Patients with respiratory tract
infections within the last 6 weeks were excluded.
Reference test—whole body plethysmography (WBP)
and bronchial provocation: the spirometric manoeuvre
performed during investigation with WBP was used as
reference test in every setting. The procedures were per-
formed according to standard protocols.26 Lung func-
tion reference values corrected for sex, age and height
were used.27 Patients with forced expiratory volume in
1 s (FEV1) <80% predicted received salbutamol with an
additional WBP investigation 20 min later. An OAD was
diagnosed if FEV1/vital capacity (VC) was ≤0.70. It was
classified as asthma if clinical symptoms and history
fitted, and if the change in FEV1 compared to baseline
was both ≥12% and ≥200 mL, and lung function
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Table 1 Characteristics of the study population
















n 154 (39.2) 5 (1.3) 234 (59.5) 75 (46.9) 25 (15.6) 8 (5.0) 52 (32.5)
Female 91 (59.1) 2 (40.0) 142 (60.7) 44 (58.7) 15 (60.0) 4 (50.0) 22 (42.3) 0.341
FENO (mean in parts per billion [SD])) 42.4 [46.4] 16.6 [6.8] 22.0 [16.5] 42.6 [47.9] 16.2 [11.1] 20.4 [18.6] 24.7 [16.0] 0.710
Age (mean in years [SD]) 40.5 [15.4] 60.8 [17.0] 44.6 [16.5] 38.7 [15.1] 55.7 [11.9] 63.5 [10.5] 42.8 [15.8] 0.684
FEV1 (mean of absolute values in L [SD]) 3.32 [0.90] 2.85 [1.72] 3.97 [1.16] 3.43 [0.76] 2.12 [0.73] 1.93 [0.55] 3.52 [0.92] 0.034
FEV1 (mean of % of predicted [SD]) 101.3 [17.0] 74.1 [12.3] 107.7 [16.3] 100 [12.2] 67.8 [18.5] 68.8 [18.4] 107.4 [12.8] <0.001
FEV1/VC (mean of % [SD]) 81.8 [8.4] 66.8 [9.8] 85.6 [7.3] 78.45 [7.02]
1 59.7 [8.4] 58.2 [7.6] 82.1 [5.8] <0.001
Do you suffer from dyspnoea attacks (yes) 33 (21.4) 1 (20.0) 32 (13.7) 27 (36.0)2 4 (16.0) 2 (25.0) 13 (25.0) <0.001
Do you suffer from dyspnoea on exertion (yes) 72 (46.8) 4 (80.0) 95 (40.6) 21 (28.0)3 16 (64.0) 4 (50.0) 14 (26.9) 0.033
Have you ever suffered from wheezing in your chest? (yes) 97 (62.9) 5 (100.0) 79 (33.8) 39 (52.0) 15 (60.0) 3 (37.5) 19 (36.5) 1.000
Do you often suffer from a cough? (yes) 65 (42.2) 3 (60.0) 112 (47.9) 32 (42.7) 15 (60.0) 4 (50.0) 40 (76.9)5 0.047
Do you often suffer from respiratory tract infections? (yes) 54 (35.1) 1 (20.0) 79 (33.8) 17 (22.7) 6 (24.0) 4 (50.0) 29 (55.8)6 0.350
Do you often suffer from expectoration? (yes) 44 (28.6) 3 (40.0) 58 (24.8) 19 (25.3) 10 (40.0) 3 (37.5) 19 (36.5) 0.532
Have you ever woken up with a feeling of tightness in your
chest? (yes)
54 (35.1) 1 (20.0) 59 (25.2) 19 (25.3) 4 (16.0) 3 (37.5) 8 (15.4) 0.070
Have you ever been woken up by an attack of shortness of
breath? (yes)
35 (22.7) 1 (20.0) 28 (12.0) 21 (28.0) 3 (12.0) 2 (25.0) 9 (17.3) 0.180
Do you suffer from any nasal allergies? (yes) 76 (49.4) 0 (0) 47 (20.1) 40 (53.3) 7 (28.0) 1 (12.5) 23 (44.2) 0.008
Do you already take medication against asthma? (yes) 17 (11.0) 1 (20.0) 8 (3.4) 19 (25.3)4 5 (20.0) 0 (0) 2 (3.8) <0.001
Do you smoke? (yes) 19 (12.3) 0 (0) 20 (8.5) 16 (21.3) 15 (60.0) 5 (62.5) 13 (25.0) <0.001
Did you ever smoke? (yes) 56 (36.4) 4 (80.0) 79 (33.8) 30 (40.0) 24 (96.0) 8 (100) 24 (46.2) 0.001
How much do/did you smoke? (mean in pack-year [SD]) 10.1 [10.7] 42.5 [3.5] 12.9 [15.8] 6.7 [13.3] 35.6 [20.6] 26.5 [17.4] 5.0 [11.1] <0.001
Values indicate the number (proportion) or mean (SD).
Subgroup differences of asthma patients from general practice versus private practice of pneumologists: 1, p<0.001; 2, p=0.002; 3, p=0.009; 4, p=0.001; Subgroup differences between patients
without OAD from general practice versus private practice of pneumologists: 5, p<0.001; 6, p=0.003.
ACOS, asthma-COPD overlap syndrome; COPD, chronic obstructive pulmonary disease; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; OAD, obstructive airway






























returned to the predicted normal range. An incomplete
bronchodilator response was stated if the response was
≥12% and ≥200 mL, but where lung volumes remained
below predicted. We labelled this group as having
asthma-COPD (chronic obstructive pulmonary disease)
overlap syndrome (ACOS), because it shows spirometric
properties of both, asthma and COPD.5 It was classified
as COPD if clinical symptoms and history fitted and the
bronchodilator response of FEV1 after salbutamol was
both <12% compared to baseline and <200 mL.3 If there
was no bronchial obstruction, bronchial provocation was
performed to determine BHR. Trained lung function
technicians measured BHR to methacholine according
to the American Thoracic Society (ATS) guideline8 in
the GP study.17 A modified bronchial provocation pro-
cedure was used in the practices of the pneumologists,18
according to the 1-concentration-4-step dosimeter proto-
col.28 This yields similar results as the ATS multiconcen-
tration protocol but is less time consuming. An ‘asthma’
diagnosis required a 20% fall in FEV1 from baseline
after inhaling methacholine stepwise until the maximum
concentration (16 mg/mL), and, alternatively, a doub-
ling of airway resistance and its increase to ≥2.0 kPa s.29
The diagnostic superiority of WPB compared with spir-
ometry for ruling out asthma was demonstrated previ-
ously.30 The final diagnosis was made under
consideration of medical history and clinical examin-
ation by a pneumologist.
Index test—FENO measurement: all patients under-
went standard measurement of FENO (NioxMino,
Aerocrine, Solna, Sweden) at a flow rate of 50 mL/s,
according to the ATS/European Respiratory Society
guideline,31 using feedback signals for control. This was
performed prior to WBP and bronchial provocation, as
the breathing manoeuvres involved could distort FENO
results. The responsible pneumologist was blinded to
the FENO results and made the diagnostic decision only
on basis of medical history, physical examination, WBP
investigation and bronchial provocation results.
Patients gave written informed consent.
Statistical methods
Power calculation was based on previous studies related
to the prevalence of asthma in the respective setting and
the diagnostic accuracy of FENO. We wanted to include
at least 149 patients in the first part of the study17 and at
least 302 patients in the second part.18 Differences
between lung function values (not normally distributed)
were statistically evaluated with the Mann-Whitney U
test. Differences between clinical symptoms were evalu-
ated with the χ2 test. The data were analysed with IBM
Statistics SPSS V.22.0 for Windows.
Independent clinical and diagnostic contributions of
symptoms and signs to the prediction of asthma were
assessed using multiple logistic regression analysis. As
the number of available variables was too large to meet
the rule of thumb in 10 cases, per independent vari-
able,32 we checked univariate associations with asthma
and included only significant variables (p<0.05) in the
model. Multiple logistic regression analysis using back-
ward elimination with p>0.1 for exclusion was per-
formed with the selected variables, resulting in the final
covariate model. Several potentially relevant interaction
terms between covariates were first included and then
removed from the model if they did not contribute to
the diagnostic accuracy. Considering the resulting covari-
ate effects estimated from the data, a rule could be
derived from the multiple logistic regression approach,
predicting the probability of asthma in each individual
case. Respective 95% CIs for predicted probabilities are
given in parentheses and were calculated using the
δ-method.33 A calculator that allows computing all com-
binations is provided as an internet supplement. If the
δ-method is not applicable, in particular at the border of
the domain of predicted probabilities, the CI is not
calculated.
In accordance with everyday practice, where an add-
itional FENO measurement is performed after medical
history information has been acquired, multiple logistic
regression analysis was repeated, adding FENO at differ-
ent cut-off values and as exact numerical variable.
Receiver operating characteristic (ROC) curves display
the diagnostic performance of the final models. The
area under the curves (AUC) were used to quantify the
added value of the CCS+FENO model beyond the
FENO model. Comparison of AUC is performed with
the empirical test implemented in NCSS V.9.0.534 using
a non-parametric approach described in DeLong et al35
and Zhou et al.36
The results of the diagnostic models were interpreted
with respect to clinical significance. A satisfactorily high
posterior probability of asthma is assumed, when the
positive predictive value is ≥70%. This corresponds with
the positive predictive value of bronchial provocation,
which was estimated around 70% for a pretest probabil-
ity of asthma of 30%,8 37 and was demonstrated
recently.30 A satisfactorily low posterior probability is
assumed at 20%, corresponding to the probability of
80% of having ‘no asthma’. This corresponds to the
negative predictive value of a 20% fall in FEV1 from
baseline during bronchial provocation.30
RESULTS
Study population
A total of 553 patients participated (320 female
(57.9%)). The recruitment rate in general practice was
76%. Nearly every patient from the practices of the
pneumologists participated; the data of seven patients
could not be used due to incompleteness (figure 1).
The diagnosis of asthma was based mainly on bronchial
provocation (n=206; 90%); positive bronchodilator
response of pre-existing airway obstruction was recorded
in only 23 (10%) cases. The prevalence of asthma was
highest in the general practice group (table 1). Patients
suffered mainly from shortness of breath, wheezing and
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cough. The patient sample from general practice suf-
fered significantly more from dyspnoea attacks, cough
and nasal allergy, and less from dyspnoea on exertion.
They used more antiasthmatic medication than patients
from the practices of the pneumologists. We found more
smokers in the general practice sample, with higher
nicotine use. Correspondingly, there were more patients
with COPD and ACOS in the general practice sample,
accompanied by a significantly lower FEV1, VC and
FEV1/VC ratio. Patients with asthma in general practice
had significantly more dyspnoea attacks and less dys-
pnoea on exertion than patients from the practices of
pneumologists (p values of subgroups are depicted at
the bottom of the table). They also used more antiasth-
matic medication. The asthma patients from the general
practice showed a significantly lower FEV1/VC ratio
compared to the patients with asthma from the pneu-
mologists practices; FEV1 and VC showed no significant
difference. Patients in general practice without OAD suf-
fered from cough and recurrent respiratory tract infec-
tions significantly more than the patients from the
practices of the pneumologists. There were no further
significant differences between the patient groups with
respect to the other CSS.
Diagnostic accuracy of FENO of the different patient
collectives
A comparison of patients from general practice and
pneumologists’ practice showed a trend towards slightly
higher sensitivities around the cut-off point >40 ppb in
the general practices; there were no remarkable differ-
ences related to specificity (table 2). Multiple logistic
regression analyses were performed with either 3, 4 or 5
selected covariates from clinical history or physical
examination, respectively. This resulted in three groups
of models and the respective equations displayed in
table 3.
Further subgroup models were defined dependent on
the treatment of FENO measures as either exact numer-
ical or dichotomised at cut-offs 10, 16, 40, 50, 60, 70 or
80 ppb. The resulting covariate effects estimated from
the data are given in table 3 as βi, i=0, 1, …, k, where k
is the number of covariates in the respective model. This
allowed the predicted probability of asthma for individ-
ual patients to be calculated. Figure 2 illustrates that the
diagnostic accuracy of FENO increases remarkably when
the results are combined with CSS. The AUC differences
were significant in general practice (p=0.001), pneumol-
ogists’ practice (p=0.0002) and in the combined sample
(p<0.0001). Beyond that, the AUCs of the general prac-
tice sample were higher than in the pneumologists’ prac-
tice sample. Box 1 gives examples of using estimate
covariate effects and equations from table 3 in order to
calculate posterior predicted probabilities of asthma
dependent on selected combinations of symptoms and
FENO measurements. In principle, diagnostic trees with
all possible posterior predicted probabilities of asthma
can be derived from table 3. The results can be com-
puted with the calculator that is added as a supplement.
Reviewing the equations (table 3), the patients’ age
turned out to be an important predictor in general prac-
tice. If the patient was 20 years old, the resulting poster-
ior probability of FENO ≥30 ppb was 87.0% (calculating
95% CI was not possible). However, it was only 66.5%
(95% CI 44.2% to 88.7%) when the patient was 50 years
old. Ruling out was only effective when a patient was suf-
fering from cough and recurrent respiratory tract infec-
tions; for example, the posterior probability of asthma
Figure 1 Diagnostic work up of
patients (ACOS, asthma-COPD
overlap syndrome; COPD, chronic
obstructive pulmonary disease;
FEV1, forced expiratory volume in
1 s; OAD, obstructive airway
disease; VC, vital capacity).
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was 18.8% (95% CI 2.1% to 35.6%) when FENO was
≤16ppb in a 20-year-old patient. Previously taken medi-
cation was strongly associated with asthma. For example,
in a 40-year-old patient, the posterior probability was
86.6% (calculating 95% CI was not possible), even when
FENO was ≤16 ppb.
The patients from the pneumologists’ practices
showed different characteristics. When a patient, inde-
pendent of age, reported wheezing and nasal allergy,
the posterior probability of asthma was 77.3% (95% CI
68.1% to 86.4%) when FENO was ≥30 ppb. Without
these symptoms, the posterior probability was only
26.2% (95% CI 14.9% to 37.5%) when FENO was
≥30 ppb. Ruling out was possible when the patient had
no allergic symptoms; with FENO ≤16 ppb, the resulting
posterior probability for asthma was 15.1% (95% CI
9.2% to 21.1%).
Wheezing, allergic rhinitis, medication, infection and
age remained as significant covariates when data of all
patients were pooled. Previously taken medication
remained as a strong predictor for asthma and was inter-
related with allergic rhinitis. Within this model, wheez-
ing and allergic rhinitis helped to rule in, and recurrent
infections helped to rule out, asthma. The positive pre-
dictive value of FENO increased considerably with
decreasing age. As an example, the final prediction rule
allowed ruling in asthma in a 20-year-old patient with
wheezing and allergic rhinitis; probability of asthma was
78.4% (95% CI 68.8% to 88.1%) when FENO was
≥30 ppb. Without wheezing but with allergic rhinitis,
p was 75.0% (95% CI 61.3% to 88.7%) when FENO was
≥50 ppb. In patients who were at least 43 years of age,
the probability of asthma was lower than 20% when
FENO was ≤16 ppb. However, ruling out in younger
patients was only effective with recurrent respiratory
tract infections when allergic signs were absent; then, as
an example, the probability of asthma was 18.1% (95%
CI 9.58% to 26.7%) when FENO was ≤16 ppb in a
20-year-old patient.
DISCUSSION
To the best of our knowledge, this is the first study to
evaluate FENO in different clinical settings in combin-
ation with CSS. We found that the selection of patients
only had a slight influence on the sensitivities of the
various FENO cut-off points. However, there was a mean-
ingful influence on diagnostic patterns. The ROC ana-
lyses illustrated that the diagnostic accuracy of FENO
increased remarkably when the test results were com-
bined with CSS.
The variation of the diagnostic accuracies of CSS
related to respiratory diseases was shown in a few
studies,1 38 illustrating that sensitivity increases and speci-
ficity decreases during the selection process of the
patients. The explanation for this phenomenon previ-
ously was worked out theoretically and methodologic-
ally.20 Whiting et al39 found, in their systematic review
about sources of variation and biases on diagnostic
accuracy of diagnostic instruments, that sensitivity
increased with disease prevalence and severity, whereas
the effects on specificity were inconsistent. This might fit





NO [ppb] Sensitivity Specificity Sensitivity Specificity
≥4 100 (97.6 to 100) 0 (0 to 1.6) 100 (95.1 to 100) 0 (0 to 4.3)
≥6 99.4 (96.5 to 99.9) 2.1 (0.9 to 4.8) 96.0 (88.9 to 98.6) 7.1 (3.3 to 14.6)
≥9 97.4 (93.5 to 99.0) 7.5 (4.8 to 11.6) 92.0 (83.6 to 96.3) 15.3 (9.2 to 24.4)
≥10 95.5 (91.0 to 97.8) 13.0 (9.3 to 17.9) 89.3 (80.3 to 94.5) 16.5 (10.1 to 25.8)
≥11 90.9 (85.3 to 94.5) 18.8 (14.4 to 24.2) 88.0 (78.7 to 93.6) 20.0 (12.9 to 29.7)
≥12 85.1 (78.6 to 89.9) 28.5 (23.2 to 34.5) 85.3 (75.6 to 91.6) 23.5 (15.8 to 33.5)
≥15 69.3 (76.6 to 82.6) 36.4 (30.6 to 42.7) 76.0 (65.2 to 84.3) 37.6 (28.1 to 48.2)
≥17 69.5 (61.8 to 76.2) 47.3 (41.1 to 53.6) 69.3 (58.1 to 78.6) 52.9 (42.4 to 63.2)
≥19 65.6 (57.8 to 72.6) 55.2 (48.9 to 61.4) 64.0 (52.7 to 73.9) 57.6 (47.0 to 67.6)
≥21 59.7 (51.8 to 67.1) 63.2 (56.9 to 69.1) 60.0 (48.7 to 70.3) 61.2 (50.6 to 70.9)
≥26 48.7 (40.9 to 56.5) 75.3 (69.5 to 80.3) 49.3 (38.3 to 60.4) 72.9 (62.6 to 81.2)
≥31 38.3 (31.0 to 46.2) 83.3 (78.1 to 87.5) 37.3 (27.2 to 48.6) 76.5 (66.5 to 84.3)
≥36 32.5 (25.6 to 40.2) 87.9 (83.2 to 91.4) 32.0 (22.5 to 43.2) 83.5 (74.2 to 89.9)
≥41 28.6 (22.1 to 36.2) 90.8 (86.5 to 93.8) 32.0 (22.5 to 43.2) 88.2 (79.6 to 93.5)
≥48 23.4 (17.4 to 30.7) 92.5 (88.4 to 95.2) 30.7 (21.4 to 41.9) 92.9 (85.4 to 96.7)
≥51 22.7 (16.8 to 29.9) 93.7 (89.9 to 96.1) 28.0 (19.1 to 39.0) 92.9 (85.4 to 96.7)
≥57 20.8 (15.1 to 27.9) 95.4 (92.0 to 97.4) 25.3 (16.8 to 36.2) 94.1 (86.9 to 97.5)
≥65 18.8 (13.4 to 25.7) 95.8 (92.5 to 97.7) 20.0 (12.5 to 30.4) 98.8 (93.6 to 99.8)
≥72 17.5 (12.3 to 24.3) 97.1 (94.1 to 98.6) 14.7 (8.4 to 24.4) 98.8 (93.6 to 99.8)
≥99 12.3 (8.0 to 18.4) 99.2 (97.1 to 99.8) 10.7 (5.5 to 19.7) 100 (95.7 to 100)
FENO, fractional exhaled nitric oxide; ppb, parts per billion.
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Table 3 Regression models of FENO (NO) and clinical signs and symptoms in different patient collectives, where k is the number of covariates in the final model
General Practice: k=5; h ¼ b0 þ b1  NOþ b2  ageþ b3 medicationþ b4  infectionþ b5  cough
Variable i βi NO exact βi NO ≤10 βi NO ≤16 βi NO ≥40 βi NO ≥50 βi NO ≥60 βi NO ≥70 βi NO ≥80
Constant 0 1.51 2.45 2.74 2.09 1.95 2.06 2.09 2.19
NO 1 0.03 −0.96 −1.05 1.03 1.53 1.91 1.89 20.82
Age 2 −0.04 −0.04 −0.04 −0.04 −0.04 −0.04 −0.04 −0.04
Medication 3 1.58 1.87 1.74 1.62 1.68 1.70 1.64 1.59
Infection 4 −1.31 −1.25 −1.23 −1.24 −1.27 −1.40 −1.29 −1.21
Cough 5 −1.04 −0.98 −1.14 −1.05 −1.02 −0.90 −0.99 −1.05
Pneumologist: k=3; h ¼ b0 þ b1  NOþ b2  wheezingþ b3  allergic rhinitis
Variable iI βi NO exact βi NO ≤10 βi NO ≤16 βi NO ≥40 βi NO ≥50 βi NO ≥60 βi NO ≥70 βi NO ≥80
Constant 0 −1.85 −1.39 −1.27 −1.55 −1.56 −1.51 −1.50 −1.50
NO 1 0.02 −0.57 −0.45 0.86 1.02 1.19 1.09 1.84
Wheezing 2 0.82 0.97 0.96 0.88 0.90 0.85 0.87 0.86
Allergic Rhinitis 3 1.28 1.43 1.40 1.33 1.38 1.37 1.37 1.34
Combined: k=6; h ¼ b0 þ b1  NOþ b2  ageþ b3  wheezingþ b4  allergic rhinitis andmedicationþ b5  allergic rhinitisþ b6  infection
Variable i βi NO exact βi NO ≤10 βi NO ≤16 βi NO ≥40 βi NO ≥50 βi NO ≥60 βi NO ≥70 βi NO ≥80
Constant 0 −0.79 −0.10 0.00 −0.43 −0.49 −0.45 −0.42 −0.47
NO 1 0.02 −0.91 −0.64 0.90 1.07 1.40 1.32 2.09
Age 2 −0.02 −0.02 −0.02 −0.02 −0.02 −0.02 −0.02 −0.01
Wheezing 3 0.66 0.83 0.82 0.74 0.75 0.70 0.72 0.71
Allergic rhinitis and medication 4 2.34 2.40 2.40 2.32 2.29 2.28 2.36 2.36
Allergic rhinitis 5 0.73 0.85 0.81 0.76 0.83 0.84 0.83 0.82






























with our findings around the critical cut-off point of
40 ppb, as the sensitivities of the various cut-off points
>40 ppb were slightly higher in the general practice
setting. The higher pretest probability in general prac-
tice might be surprising at first sight. This could be
explained by the study design, which required that par-
ticipating patients had to travel to the lung function
laboratory of the University Medical Hospital
Heidelberg, which might have unintentionally caused a
selection of patients with a higher probability and/or
severity of disease. It might explain why ruling in the
diagnosis of asthma appeared more straightforward in
the general practice sample than in the pneumologists’
sample. In the latter, ruling in of asthma was only rea-
sonable with FENO ≥30 ppb, when the patient suffered
from wheezing and allergic rhinitis.
The strength of both settings was that only diagnostic-
ally naive patients presenting for the first time for diag-
nostic investigation were included. As we observed no
strong influence of the setting on the sensitivities and
specificities of FENO cut-points, we pooled the data of
all patients. The AUC increased remarkably from 0.650
to 0.753 when CSS were included in the diagnostic
model. The final prediction rule conclusively illustrates
that the potential of FENO to rule in or rule out asthma
depends on the age of patients and the presentation of
CSS. This might explain why varying cut-off points were
found in the different studies when various patient
collectives were evaluated. The prediction rule revealed
that, especially, allergic rhinitis and wheezing are helpful
to identify patients who will benefit from FENO meas-
urement in terms of a high positive predictive value.
This fits in with previous studies illustrating the relation-
ship between asthma, increased FENO values, wheez-
ing40 and allergic rhinitis,41 which is explained by the
common type of eosinophilic inflammation.12 Thus it
seems possible to diagnose asthma with FENO ≥30 ppb
in patients with a compatible medical history, which is
20 ppb lower, as suggested by the ATS guideline.15
Another important point is the strong impact of previ-
ously given medication on the diagnostic model.
Medications are prescribed occasionally ‘ex juvantibus’
in case of clinical uncertainty in general practice when
asthma is suspected.42 This is crucial to avoid deterior-
ation of asthma until the definite diagnosis is established
by bronchial provocation in the practices of pneumolo-
gists or in a hospital. Thus, there seems to be a high
probability of asthma when the patient continues
inhaler therapy.
It was difficult to exclude the diagnosis of asthma in
younger patients solely on the basis of FENO measure-
ment. In general practice, it was only possible when
there were no specific allergic signs, FENO measure-
ment showed low values and the patient was suffering
from recurrent respiratory tract infections and cough.
The latter appears contradictory to guidelines.5
However, the negative association with cough was
already shown previously1 43 and seems reasonable from
Figure 2 Receiver operating characteristic curves of
fractional exhaled nitric oxide and clinical signs and
symptoms.
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a clinical point of view, as many patients in general
practice are coughing and/or have respiratory tract
infections, but only few are really suffering from
asthma. The low performance of ruling out asthma
might be explained by the blind spot of FENO regard-
ing neutrophilic inflammation.18 44 Patients with this
type of inflammatory pattern are less responsive to
inhaled corticosteroids, but absence of eosinophilia
does not indicate an absence of steroid response.45
Therefore, patients with negative test results have to be
referred for bronchial provocation in case of persistent
symptoms, to definitely rule in or rule out the diagnosis
of asthma.
The strength of the study is that the diagnostic accur-
acy of FENO was evaluated in two different settings. This
was accompanied by the use of two slightly different ref-
erence standards with respect to bronchial provocation,
which could have influenced the evaluation. However,
the 1-concentration-4-step dosimeter protocol shows
results similar to the ATS multiconcentration protocol.28
Thus, a major distortion seems unlikely. We used the
maximum concentration of methacholine for bronchial
provocation as a reference standard to rule in and rule
out asthma. Consequently, borderline bronchial hyper-
reactivity also led to the diagnosis of asthma.8 Therefore,
the potential of FENO for ruling out moderate and
severe asthma might be underestimated.17 Further diag-
nostic studies would be necessary for differentiation of
such subgroups, in particular with respect to the neces-
sity for therapy with inhaled corticosteroids. Another
inherent limitation is that two different patient collec-
tives were used for analysis. However, recruitment in dif-
ferent settings was intended to analyse potentially
different diagnostic patterns. It might be speculated
whether two different diagnostic algorithms related to
each practice setting need to be used. The general prac-
tice patients seemed to be comparatively selected, which
might be explained by the study design. Therefore it
appeared adequate to extrapolate our FENO findings
more cautiously to allow generalisation of the diagnostic
algorithm. Thus we decided to pool the data of both
patient samples, because the clinical setting had only a
minor influence on the sensitivities of the various cut-off
points of FENO. As a result, the final model fitted well
Box 1 Derivation of probability test for asthma




in which h ¼ b0 þ b1  FENOþ b2  wheezingþ b3  allergic rhinitis for the pneumologist model, where β0 is the estimated coefficient of
the grand mean in the model and β1, β2 and β3 are the regression coefficients of the variables in the model.
Examples of calculations for the final models are given below:
Pneumologist model using exact numerical values for fractional exhaled nitric oxide (FENO):
h ¼ 1:85þ 0:02 80 ¼ 0:25 if patient has FENO ¼ 80 ppb
þ 0:82whenwheezingwas present;
þ 1:28when allergic rhinitis was present;
þ 0:82þ 1:28 ¼ 2:1whenwheezing and at the same time allergic rhinitis were present:
Examples
A patient with wheezing, allergic rhinitis and a FENO value of 80 ppb has a prediction score of −0.25+2.1=1.85, resulting in a probability of
84.1% (95% CI 75.5% to 92.7%) of having asthma. Similarly, a patient with wheezing and FENO=80 ppb, but no allergic rhinitis, has a
probability of 59.5% (95% CI 44.1% to 74.8%) of having asthma. A patient without any of these two items, however, with FENO=80 ppb,
has a predicted probability of 39.3% (95% CI 22.8% to 55.9%) of having asthma.
Pneumologist model using a cut-off value <16 ppb for FENO:
h ¼ 1:27
 0:45 ¼ 1:72when FENOmeasurement was less or equal to 16 ppb;
 0:45þ 0:96 ¼ 0:76whenwheezingwas present additionally;
 0:45þ 0:96þ 1:4 ¼ 0:64when in addition to wheezing and FENO 16 ppb allergic rhinitis was present:
Examples
A patient with FENO measurement less or equal to 16 ppb, wheezing and allergic rhinitis has a probability of 65.3% (95% CI 52.7% to
78.0%) of having asthma. Similarly, a patient with the same symptoms and same FENO measurement, but without allergic rhinitis, has a
probability of 31.8% (95% CI 21.6% to 42.0%) of having asthma. A patient without any of these items, but FENO below 16 ppb, has a prob-
ability of 15.1% (95% CI 9.2% to 21.1%) of having asthma. Conversely, this means a probability of 84.9% (95% CI 78.9% to 90.8%), for
this group of patients, of not having asthma.
According to these calculations, predicted probabilities for the sputum and general practice patients can be calculated.
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with the established clinical decision rules used by many
physicians and led to a more conservative interpretation
of the FENO measurements. However, a validation study
would be desirable to confirm our findings.
Another crucial issue is to decide the ideal cut-off
point with respect to clinical significance. FENO
≥30 ppb resulting in a probability of asthma of 78.4%
might be regarded as too low. However, this is consider-
ably better than the predictive value of bronchial provo-
cation with methacholine.8 30 37 Ruling out asthma with
FENO ≤16 ppb is equal to a 20% fall of FEV1 during
bronchial provocation, which can be detected with spir-
ometry manoeuvres. However, the negative predictive
value of specific airway resistance response on metha-
choline as determined with WBP would be much lower
with a negative predictive value of 97.8%.30 Finally, eight
patients with ACOS were labelled as non-asthmatics
because of the uncertainty of their diagnostic entity.
However, we expect that this did not distort the results,
due to the low number of cases.
CONCLUSION
The ROC analysis revealed that FENO results should be
interpreted in the context of CSS to enhance their diag-
nostic value in primary care. The final diagnostic model
appears as a sound primary care algorithm fitting to the
established diagnostic rules related to CSS of asthma.
Importantly, FENO appears more promising for ruling
in asthma than for ruling it out. Ruling in asthma with
FENO ≥30 ppb is reasonable when allergic symptoms
such as wheezing and allergic rhinitis are present.
Previously taken medication is a strong predictor for
asthma. Ruling out younger patients only seems possible
in case of recurrent respiratory tract infections when no
allergic symptoms are present.
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